Challenges in the development of an autologous heat shock protein based anti-tumor vaccine.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 3551892)

Published in Hum Vaccin Immunother on August 01, 2012

Authors

Dirk J Reitsma1, Austin J Combest

Author Affiliations

1: PPD, Wilmington, NC USA. Dirk.Reitsma@ppdi.com

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72

The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther (2009) 5.01

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet (2008) 4.11

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol (2002) 3.03

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 2.92

The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res (2006) 2.48

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 2.25

Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J (2003) 1.60

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res (2006) 1.44

How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol (2011) 1.43

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30

The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med (1999) 1.27

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol (2005) 1.26

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine (2005) 1.04

Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer (2012) 1.00

The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones (2000) 0.93

Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am (2000) 0.91

Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun (2001) 0.89

Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol Biol (2001) 0.88

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer (2008) 0.85